AU2020266283A1 - Antibodies binding to plasmodium circumsporozoite protein and uses thereof - Google Patents

Antibodies binding to plasmodium circumsporozoite protein and uses thereof Download PDF

Info

Publication number
AU2020266283A1
AU2020266283A1 AU2020266283A AU2020266283A AU2020266283A1 AU 2020266283 A1 AU2020266283 A1 AU 2020266283A1 AU 2020266283 A AU2020266283 A AU 2020266283A AU 2020266283 A AU2020266283 A AU 2020266283A AU 2020266283 A1 AU2020266283 A1 AU 2020266283A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020266283A
Other languages
English (en)
Inventor
Elisabetta CAMERONI
Davide Corti
Katja Fink
Luca PICCOLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Vir Biotechnology Inc
Original Assignee
Humabs Biomed SA
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA, Vir Biotechnology Inc filed Critical Humabs Biomed SA
Publication of AU2020266283A1 publication Critical patent/AU2020266283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2020266283A 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof Abandoned AU2020266283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/061135 WO2020221451A1 (en) 2019-04-30 2019-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof
AUPCT/EP2019/061135 2019-04-30
PCT/EP2020/062167 WO2020221910A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Publications (1)

Publication Number Publication Date
AU2020266283A1 true AU2020266283A1 (en) 2021-09-02

Family

ID=66429360

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020266283A Abandoned AU2020266283A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Country Status (13)

Country Link
US (1) US20230084102A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962513A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531552A (cg-RX-API-DMAC7.html)
KR (1) KR20220004055A (cg-RX-API-DMAC7.html)
CN (1) CN114206921B (cg-RX-API-DMAC7.html)
AU (1) AU2020266283A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130805A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192930A1 (cg-RX-API-DMAC7.html)
IL (1) IL285282A (cg-RX-API-DMAC7.html)
MX (1) MX2021013252A (cg-RX-API-DMAC7.html)
SG (1) SG11202108585QA (cg-RX-API-DMAC7.html)
WO (2) WO2020221451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
US20240287166A1 (en) * 2021-05-28 2024-08-29 David Weiner Dna antibody constructs for use against plasmodium parasites
CN117467005A (zh) * 2023-11-15 2024-01-30 深圳重链生物科技有限公司 抗疟原虫单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用
EP3612562A2 (en) * 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Also Published As

Publication number Publication date
CN114206921B (zh) 2024-05-14
WO2020221451A1 (en) 2020-11-05
BR112021016341A2 (pt) 2021-10-26
SG11202108585QA (en) 2021-11-29
MX2021013252A (es) 2021-11-17
CN114206921A (zh) 2022-03-18
US20230084102A1 (en) 2023-03-16
IL285282A (en) 2021-09-30
JP2022531552A (ja) 2022-07-07
WO2020221910A1 (en) 2020-11-05
KR20220004055A (ko) 2022-01-11
EP3962513A1 (en) 2022-03-09
CA3130805A1 (en) 2020-11-05
EA202192930A1 (ru) 2022-02-24

Similar Documents

Publication Publication Date Title
US12421314B2 (en) Binding molecules specific for fcγRIIA and uses thereof
JP7498714B2 (ja) B型肝炎ウイルスを中和する抗体およびその使用
US11919954B2 (en) Anti-TREM-1 antibodies and uses thereof
KR20140108520A (ko) CD1d에 대한 항체
US20230084102A1 (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
WO2020260315A1 (en) Deimmunized antibodies binding to alpha-4 integrin and uses thereof
US20250129142A1 (en) Antibodies binding to tetanus toxin and uses thereof
OA20886A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof.
US20240034772A1 (en) Antibodies binding to f-protein of metapneumovirus and uses thereof
HK40070165A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
WO2025045250A1 (en) Anti-human factor d antibody constructs and uses thereof
WO2025171256A1 (en) Compositions and methods for treating malaria
CN116848133A (zh) 结合偏肺病毒f蛋白的抗体及其用途
WO2026008055A1 (zh) 抗kit抗体及其医药用途
KR20250126016A (ko) 항인간 cx3cr1 항체
KR20250043535A (ko) 칸나비노이드 유형 1 수용체 결합 단백질 및 이의 용도
KR20250059447A (ko) 항-ilt4 항체 및 이의 의약적 용도
IL322413A (en) Variants of anti-CSP antibody
NZ622050B2 (en) ANTIBODIES TO CD1d

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application